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D-serine is an endogenous N-methyl-D-aspartate
(NMDA) receptor coagonist. It is synthesized from L-
serine by serine racemase (SRR), but many aspects of
its metabolism remain unclear, especially in the fore-
brain, which lacks active D-amino acid oxidase (DAO),
the major D-serine degradative enzyme. Candidate
mechanisms include SRR operating in a,b-eliminase
mode (converting D-serine to pyruvate) and regulation
by serine transport, in which the alanine-serine-cysteine
transporter ASCT2 is implicated. Here we report stud-
ies in C6 glioma cells, which ‘‘simulate’’ the forebrain,
in that the cells express SRR and ASCT2 but lack DAO
activity. We measured D-serine, ASCT2, SRR, and DAO
expression and DAO activity in two situations: after
incubation of cells for 48 hr with serine isomers and af-
ter increased or decreased SRR expression by trans-
fection and RNA interference, respectively. Incubation
with serine enantiomers decreased [
3H]D-serine uptake
and ASCT2 mRNA and increased SRR immunoreactiv-
ity but did not alter DAO immunoreactivity, and DAO
activity remained undetectable. SRR overexpression
increased D-serine and pyruvate and decreased [
3H]D-
serine uptake and ASCT2 mRNA but did not affect
DAO. SRR knockdown did not alter any of the parame-
ters. Our data suggest that D-serine transport mediated
by ASCT2 contributes prominently to D-serine homeo-
stasis when DAO activity is absent. The factors regulat-
ing D-serine are important for understanding normal
NMDA receptor function and because D-serine, along
with DAO and SRR, is implicated in the pathogenesis
and treatment of schizophrenia. V V C 2010 Wiley-Liss, Inc.
Key words: D-serine; eliminase; racemase; uptake;
transporter; glia; DAAO
The neutral amino acid D-serine acts on the gly-
cine binding site of the N-methyl-D-aspartate receptor
(NMDAR) and modulates glutamate-mediated receptor
activation. The importance of D-serine in mammalian
brain function is apparent from extensive investigations
(for reviews see Snyder and Kim, 2000; Martineau et al.,
2006), including roles in synaptic plasticity (Zhang et al.,
2008) and memory (Duffy et al., 2008). Furthermore,
D-serine is implicated in the pathophysiology and ther-
apy of several psychiatric and neurological conditions
(Martineau et al., 2006). In schizophrenia, there is evi-
dence that D-serine levels are decreased (Hashimoto
et al., 2005; Bendikov et al., 2007), a deﬁciency that
may contribute to the proposed NMDAR hypofunction
of the disorder (Olney and Farber, 1995; Coyle et al.,
2003) and that has led to D-serine replenishment as a
novel therapeutic strategy (Coyle and Tsai, 2004; Tuo-
minen et al., 2005).
D-serine is synthesized from L-serine by serine
racemase (SRR), and it is degraded by D-amino acid
oxidase (DAO). In the brain, both SRR and DAO are
primarily but not exclusively localized to glial cells
(Wolosker et al., 1999; Mustafa et al., 2004; Kartvelish-
vily et al., 2006; Miya et al., 2008). D-serine uptake into
glial cells is mediated largely by ASCT2 (Hayashi et al.,
1997; Shao et al., 2009). Beyond the basic details, how-
ever, much remains unclear about how D-serine levels
are regulated. A speciﬁc complexity pertains in the cere-
bral cortex, wherein D-serine and SRR are abundant
(Schell et al., 1995, 1997; Wolosker et al., 1999), and,
although DAO is expressed (Bendikov et al., 2007; Ver-
rall et al., 2007), its activity is minimal (Horiike et al.,
1994; Wang and Zhu, 2003). There are two possibilities
for cortical D-serine regulation in the virtual absence of
DAO. One is that SRR can remove D-serine via an
a,b-eliminase reaction (Foltyn et al., 2005) that occurs
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' 2010 Wiley-Liss, Inc.in addition to, rather than in lieu of, its racemase activity
(Panizzutti et al., 2001; Strı ´sovsky ´ et al., 2003, 2005;
Nagayoshi et al., 2009). SRR may also operate in
reverse racemase mode, converting D- to L-serine
(Foltyn et al., 2005). This multifunctional capability of
SRR could therefore be sufﬁcient to regulate D-serine
in the forebrain and thus, preclude the need for active
DAO. A second possible mechanism of D-serine regula-
tion may be via transport and recycling between cells
and synapses (and between periphery and brain) rather
than via degradation. Given that ASCT2 modulates the
levels of its high-afﬁnity substrate glutamine (Dolin ´ska
et al., 2001), it is reasonable to propose that it might
also regulate intracellular D-serine homeostasis.
Given the major role of glia in D-serine metabo-
lism, glial cells provide a useful in vitro model system
with which to investigate these issues (Shoji et al.,
2006a; Martineau et al., 2008). Moreover, the rat C6
glioma cells lack functional DAO despite expressing it
(Park et al., 2006; Burnet et al., 2009). These cells are
useful for studying D-serine in a cellular environment
that lacks DAO, because in this respect they ‘‘simulate’’
the situation in the forebrain. Here we have studied C6
cells to address two main questions. 1) Which compo-
nents of serine metabolism (SRR, DAO, D-serine
uptake, and ASCT2) respond to changes in serine con-
centrations in glial cells that, at least under basal condi-
tions, have no active DAO? We have measured SRR
and DAO expression and activity, [
3H]D-serine uptake,
and ASCT2 mRNA expression in C6 glioma cells 48 hr
after the addition of serine isomers. 2) What inﬂuence
does increased and decreased expression of SRR,
achieved by transfection and RNA interference, respec-
tively, have on the same parameters? Some of these data
have been presented in abstract form (Burnet et al.,
2009).
MATERIALS AND METHODS
Materials
2,20-Azino-bis(3-ethylbenzthiazoline-6-sulphonic acid;
ABTS), Bradford reagent, Dulbecco’s modiﬁed Eagle’s me-
dium (DMEM), glutaraldehyde, L-glutamine, fetal calf serum
(FCS), L- and D-serine, D-proline, 0.25% tripsin/EDTA solu-
tion, Kodak BioMax X-Omat AR ﬁlm, RIPA buffer, and Tri
reagent were purchased from Sigma-Aldrich (Poole, United
Kingdom). The ‘‘Kaleidescope’’ protein molecular weight
marker and the chemiluminescence ECL-Plus kit were pur-
chased from GE Healthcare (Buckinghamshire, United King-
dom). Polyclonal anti-mouse SRR and anti-D-serine were
purchased from Bioline and Abcam (Cambridge, United
Kingdom), respectively. Polyclonal anti-human DAO was a
generous gift from Dr James Kew (GSK, Harlow, United
Kingdom), and anti-rabbit and anti-mouse peroxidise-linked
(HRP-linked) antisera were purchased from Bio-Rad. Polyvi-
nyl diﬂuoride (PVDF) membranes were purchased from
Immobilon-P (Millipore, Watford, United Kingdom). [
3H]D-
serine (25 Ci/mmol) was purchased from Perkin Elmer (Nor-
walk, CT). The pyruvate assay was purchased from BioVision
United Kingdom. Turbofect was purchased from Fermentas.
The pcDNA3.1 and pcDNAEGFP plasmids and Amplex red
were purchased from Invitrogen.
Cell Culture
Rat glioma C6 cells (from the European collection of
Animal Cell Cultures; ECACC) were cultured in Dulbecco’s
modiﬁed Eagle’s medium containing 10% (v/v) FCS and sup-
plemented with 2 mM L-glutamine, at 378C in a humidiﬁed
atmosphere of 5% CO2. For all experiments, C6 cells were
seeded into six-well plates (2 3 10
5 cells in 2 ml growth me-
dium in each well) and allowed to adhere for 24 hr. The cul-
ture medium was then replaced with either fresh medium
containing plasmid lipid complexes (see below) or L- or D-
serine or D-proline at a ﬁnal concentration of 2 or 20 mM,
which are similar to the amounts of D-amino acids used in
other studies of C6 cells (Park et al., 2006). D-proline is not
transported into C6 cells and therefore was chosen as a control
for extracellular hypertonicity, which occurs when amino
acids are added to the culture medium. In all studies, cells
were incubated for 48 hr following pharmacological or molec-
ular intervention.
Western Blotting
C6 cells were harvested with 0.25% trypsin/EDTA solu-
tion, transferred to a 1.5-ml microfuge tube, and centrifuged
for 1 min at 12,000g. The cell pellet from two wells of the
control and experimental condition was solubilized in 40 ll
RIPA buffer and used for Western blotting as previously
described (Verrall et al., 2007). The remaining cells were used
for RNA extraction (see below). Brieﬂy, 16 lg protein from
each sample was loaded into separate wells of a 12% SDS/
polyacrylamide gel and fractionated by electrophoresis along
side a ‘‘Kaleidascope’’ molecular weight marker. Pilot studies
established that 16 lg protein allowed the detection of SRR,
DAO, and b-actin immunoreactivities within the linear range.
Fractionated samples were then transblotted onto PVDF
membranes.
The membranes were blocked with 2% (w/v) nonfat
milk in PBS containing 0.1% Tween 20 (PBST) for 1 hr and
then incubated with primary antibody (anti-mouse SRR,
1:1,000; anti-human DAO, 1:1,000) in PBST containing 1%
(w/v) BSA for 1.5 hr at room temperature. Membranes were
then washed three times for 10 min each in PBST and incu-
bated for 1 hr in HRP-linked anti-mouse or anti-rabbit
antibody in blocking buffer. Immunoreactive bands were
visualized by chemiluminescence using the ECL-Plus kit and
apposing membranes to X-ray ﬁlm.
RT-PCR
Total RNA was extracted from cells using the Tri rea-
gent method. Reverse transcription of 2 lg RNA and PCR
were performed as previously described (Burnet et al., 2008),
using primers against rat ASCT2 (forward 1250–1272 bp;
reverse 1481–1500 bp; accession No. NM_175758), SRR
(forward 841–863 bp; reverse 1082–1101 bp; accession No.
NM_198757), DAO (forward 571–593 bp; reverse 801–822
bp; accession No. NM_053626), or GAPDH (forward 11–34
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ﬁcation parameters for each gene were 948C, 30 sec; 628C,
30 sec; 728C, 1 min; for up to 35 cycles. Amplimers were
fractionated on a 2% agarose gel in Tris-acetate-EDTA (TAE)
buffer, pH 7.4, containing 5 lg/ml ethidium bromide. Bands
were visualized with UV illumination using an Alpha Imager
3400. Nonsaturating levels of each amplimer were predeter-
mined by removing a sample of the reaction mix during
ampliﬁcation after several cycles (25–35) and visualizing them
on a gel. The amplimer intensities were plotted against cycle
number to determine the cycles required to achieve about
50% intensity (ampliﬁcation) of each gene. For quantitative
analysis, the abundance of ASCT2 mRNA was expressed as
ratio of ASCT2/GAPDH intensities.
D-Serine Uptake
The uptake of D-serine into C6 cells was performed
according to the method described by Hayashi et al. (1997).
Brieﬂy, adhered cells were preincubated with 1 ml uptake
buffer (5 mM HEPES, 5 mM KCl, 1 mM KH2PO4, 140 mM
NaCl, 1.8 mM CaCl2, 0.4 mM MgSO4, 5 mM D-glucose,
adjusted to pH 7.4 with NaOH) for 10 min at 378C. The
uptake reaction was initiated by the addition of 0.2 ml of the
uptake buffer containing [
3H]D-serine; for saturation experi-
ments, a range of [
3H]D-serine concentrations (1–8 mM) was
used. Nonspeciﬁc uptake of [
3H]D-serine was estimated by
performing the same experiments on ice (0–48C). After incu-
bation for 10 min at 378C, the reaction was stopped by wash-
ing cells three times in 1 ml ice-cold uptake buffer. Cells
were then solubilized with 0.1 M NaOH (500 ll), of which
400 ll was used to determine accumulated radioactivity by
liquid scintillation spectroscopy and the remainder to measure
protein concentrations in each sample. Speciﬁc [
3H]D-serine
uptake was deﬁned as the difference between values obtained
at 378C vs. 0–48C. The uptake of [
3H]D-serine into manipu-
lated or amino-acid-treated C6 cells was determined at
the Km. This was calculated from an Eadie-Hofstee plot of
the saturation data (Hayashi et al., 1997), where the Km was
the reciprocal of the slope of the graph.
D-Serine and Pyruvate Measurements
The measurement of D-serine and pyruvate concentra-
tions were used as indices of SRR racemase and a,b-elimi-
nase activities, respectively. The D-serine enzyme-linked
immunosorbant assay (ELISA) was performed by using a mod-
iﬁcation of a recently reported protocol (Zhang et al., 2008).
Cells were detached from wells with 0.25% trypsin/EDTA so-
lution and pelleted in 1.5-ml Eppendorf tubes. Cell pellets
were then homogenized in ice-cold distilled water, and debris
was removed by centrifugation. The concentration (mg/ml)
of soluble protein in each sample was determined by using the
Bradford reagent for colorimetric measurements at 595 nm,
with BSA standards. Protein in each extract was adjusted to
0.5 mg/ml with water. Twenty-ﬁve microlitres of glutaralde-
hyde was added to 100 ll of each extract or D-serine stand-
ards (0.06–15 nmol/ml) in PBS containing 0.2 mg/ml BSA
(resulting in a ﬁnal concentration range of D-serine standards
of 0.02–5 nmol). The solutions were mixed thoroughly, and
50-ll triplicates of this were added to an ELISA plate. After a
2-hr incubation at room temperature, wells were washed with
PBST and air dried. Blocking buffer (2% nonfat milk in
PBST, 50 ll) was added to the wells and incubated for 30
min at room temperature. Plates were then washed three
times in PBST (300 ll/well). The D-serine speciﬁc antibody
was diluted 1:1,000 in PBST containing 1% BSA. Fifty micro-
liters was added to each well and incubated for 1 hr, followed
by three washes with PBST. The HRP-linked anti-rabbit
antibody was then added for 30 min, followed by three
washes in PBST. A colorimetric reaction initiated by the addi-
tion of 50 ll ABTS to each well was measured at 405 nm.
In separate experiments, cell pellets (see above) were
resuspended in 50 ll water and then boiled for 5 min to
denature endogenous lactate dehydrogenase in the samples
(De Miranda et al., 2002). Preliminary experiments conﬁrmed
that boiling and did not degrade sodium pyruvate (not
shown). The suspensions were then centrifuged to remove
cell debris, and the supernatants were retained for analysis.
The concentration of pyruvate in all samples and boiled
sodium pyruvate standards (40–200 mM) was estimated in a
pyruvate oxidase-based colorimetric assay (Biovision).
DAO Activity Assays
DAO activity was measured via the estimation of
hydrogen peroxide formation as previously described (Burnet
et al., 2008). Brieﬂy, control and experimental cells were har-
vested from cell culture plates as described above and centri-
fuged at 12,000g for 1 min. Cell pellets were then homoge-
nized in cold sodium phosphate buffer (50 mM Na2HPO4,
pH 8.0) on ice. Ten microliters of the homogenate was added
to a solution of Amplex red (0.5 lg), horseradish peroxidise
(10 lg), and D-proline (50 mM) in a total volume of 20 ll
phosphate buffer. After 1 hr of incubation at 378C, cell debris
was pelleted, and the absorbance of the supernatant was meas-
ured at 571 nm. Baseline measurements were made in reac-
tion solutions that did not contain D-proline. DAO activity in
C6 cells transfected with recombinant rat DAO (rDAO),
using similar methods, was also determined. Synthesis of the
rDAO is described below.
Overexpression and RNA Interference
For overexpression studies, the open reading frames of
rat SRR (accession No. NM_198757) and rat DAO (accession
No. NM_053626) were ampliﬁed and cloned into the pcDNA
3.1 vector using standard protocols. The pcDNAEGFP
construct was used as a control plasmid. The C6 cells were
transfected with SRR, DAO, or enhanced green ﬂuorescent
protein (EGFP) plasmids 16 hr after seeding into six-well
plates, using TurboFect according to the manufacturer’s rec-
ommendations. A total of 3 lg of DNA was added to each
well, ensuring that for each plate three wells received pcDNA-
EGFP (control transfection) and the other three wells received
SRR or DAO (experimental transfection). Cells were then
incubated for a further 48 hr, prior to protein extraction,
DAO activity assays, D-serine uptake studies, and measure-
ments of D-serine and pyruvate.
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(shRNAs) were purchased from Sigma-Genosys. Two of the
shRNA plasmids targeting the rat SRR open reading frame
(referred to as ‘‘sh596’’ and ‘‘sh886’’) were transfected into C6
cells as described above, with pEGFP as the control in three
wells of each six-well plate of cells. Cells were harvested 48
hr after transfection, and extracts were prepared for the meas-
urements described for SRR overexpression.
Data Analysis
All cell-culture data were analyzed by paired-samples t-
test (SPSS version 15 for Windows), to compare control with
experimentally manipulated cells in each plate.
RESULTS
Expression of DAO, SRR, and ASCT2 in C6 Cells
Western blots of SRR and DAO immunoreactivity
in C6 cells, relative to b-actin are shown in Figure
1A,B. Both enzyme proteins were expressed as a major
band migrating at the predicted weights ( 38 kDa),
with an additional minor DAO band at  30 kDa (Fig.
1B). The different afﬁnities and dilutions of each anti-
body did not allow the direct comparison of the relative
levels of each enzyme in protein extracts. However, the
abundance of SRR mRNA was severalfold higher than
that of DAO mRNA relative to GAPDH mRNA in
RT-PCR experiments (Fig. 1C).
Concentration-dependent [
3H]D-serine uptake was
demonstrated in C6 cells (Fig. 1D). The afﬁnity for
[
3H]D-serine transport into C6 cells (Km 5 2.54 6
0.15 mM) was similar to a published value of 2.48 6
0.08 mM (Hayashi et al., 1997). Subsequent [
3H]D-ser-
ine uptake experiments were performed at 2.5 mM.
ASCT2 mRNA was readily detectable (Fig. 1C) and
was similar to SRR mRNA abundance.
Effect of Serine Isomers on SRR and DAO
Immunoreactivity
The addition of 20 mM L-serine (Fig. 2A) or D-
serine (Fig. 2C) but not D-proline (Fig. 2E) to the cul-
ture medium increased the expression of SRR in C6
cells after 48 hr of incubation (L-serine: t 5 –5.44, P 5
0.003; D-serine: t 5 –4.21, P 5 0.008; D-proline: t 5
0.43, P 5 0.493). The lack of effect of D-proline dem-
onstrated that the observed changes were not secondary
to a hypertonic medium. None of the amino acids
affected DAO immunoreactivity (Fig. 2B,D,F), and
DAO activity remained undetectable (detection limit of
assay in the absence of D-proline at 571 nm/mg pro-
tein/min 5 0.02 6 0.001), except after rDAO transfec-
Fig. 1. SRR, DAO, and ASCT2 expression and [
3H]D-serine
uptake in C6 glioma cells. A: Representative Western blots of
SRR and b-actin in C6 cell extracts from two separate culture
wells. B: DAO and b-actin Western blots of C6 cell extracts.
Arrowhead indicates an additional minor band migrating at 30 kDa.
C: Ethidium bromide-stained agarose gels demonstrating the rela-
tive abundance of ASCT2, DAO, SRR, and GAPDH mRNAs in
C6 cells, determined by RT-PCR. D: Uptake of [
3H]D-serine
into C6 cells. Data points are mean 6 SEM from four experi-
ments. Inset shows an Eadie-Hofstee plot of these data for the cal-
culation of Km.
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assay (571 nm/mg protein/min 5 0.29 6 0.02). The
same effects on SRR immunoreactivity were observed
with 1 mM of serine isomers, the magnitude of SRR
increase being approximately one ﬁfth of that observed
with 20 mM (data not presented).
Effect of Serine Isomers on [
3H]D-Serine Uptake
and ASCT2 mRNA
Cells incubated for 48 hr with 20 mM D-serine
(Fig. 3A) or L-serine (Fig. 3B) had signiﬁcantly reduced
uptake of [
3H]D-serine compared with controls and cells
Fig. 2. Effect of 20 mM serine isomers and D-proline on SRR and DAO immunoreactivity relative to
b-actin in C6 cells. A: Increased SRR in cells after a 48-hr exposure to L-serine. B: No effect of L-ser-
ine on DAO expression. C: Increased SRR expression in cells after a 48-hr exposure to D-serine.
D: No effect of D-serine on DAO. The administration of D-proline (20 mM) to cells did not alter SRR
(E) or DAO (F). *P < 0.01
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P 5 0.007; L-serine: t 5 8.5, P < 0.001; D-proline:
t 5 –0.547. P 5 0.591). RT-PCR demonstrated
reduced ASCT2 mRNA in C6 cells treated with L-
or D-serine compared with controls, paralleling the
reduced D-serine uptake in the same cells (Fig. 3D;
L-serine: t 5 5.214, P 5 0.003; D-serine: t 5 5.619,
P 5 0.002; D-proline: t 5 1.549, P 5 0.182).
D-Serine and Pyruvate Concentrations After
Serine Incubation
A representative ELISA standard curve using a
solution of D-serine/BSA conjugate is shown in Figure
4A; the detection limit was approximately 0.01 nmol/
mg protein of cell extract. The addition of 1 mM and
20 mM D-serine to C6 cells produced a half (t 5 –
5.573, P 5 0.003) and a fourfold (t 5 –10.747, P <
0.001) elevation in intracellular D-serine concentration,
respectively, compared with controls (Fig. 4B). By
contrast, the concentration of D-serine in cells incu-
bated for 48 hr with 1 and 20 mM L-serine did not
signiﬁcantly differ from controls (Fig. 4C). The con-
centration of intracellular pyruvate was also unaltered
after incubation with exogenous serine enantiomers
(Fig. 4D).
DAO, [
3H]D-Serine Uptake, and ASCT2 mRNA
Following SRR Overexpression and Knockdown
Results of the expression of recombinant rat SRR
(CMV-SRR) in C6 cells is shown in Figure 5A. An
overall twofold increase in SRR immunoreactivity was
achieved (t 5 –4.196, P 5 0.009). This did not affect
DAO immunoreactivity (t 5 1.79, P 5 0.133; Fig. 5B)
or DAO activity (remaining undetectable) but did
decrease D-serine uptake (t 5 6.22, P 5 0.002; Fig. 5C)
and ASCT2 mRNA expression (t 5 3.26, P 5 0.022;
Fig. 5D) compared with controls. The intracellular con-
centrations of D-serine and pyruvate were also increased
48 hr after transfection with CMV-SRR (Table I).
SRR immunoreactivity was reduced by approxi-
mately half when C6 cells were incubated for 48 hr after
transfection with plasmid sh886 (t 5 4.691, P 5 0.005;
Fig. 6A). Transfection with plasmid sh596 did not elicit
a decrease in SRR protein (not shown). Cell viability
did not appear to be affected by shRNAs as determined
through cell counting with trypan blue (data not
Fig. 3. Effect of 48-hr exposure to 20 mM serine isomers and D-proline on [
3H]D-serine uptake into
C6 cells and ASCT2 expression. A: Reduced [
3H]D-serine uptake after a 48-hr exposure to D-serine.
B: Reduced [
3H]D-serine uptake after exposure to L-serine. C: No effect of D-proline on [
3H]D-serine
uptake. D: L- and D-serine, but not D-proline, decreased ASCT2 mRNA (hatched bars) relative to con-
trols (open bars). *P < 0.01, n 5 6 for each condition.
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uptake, ASCT2 mRNA, D-serine, and pyruvate in C6
cells transfected with sh886 were similar to controls (Fig.
6B–D, Tables I, II).
DISCUSSION
The current study sought to explore the roles of
SRR, DAO, and ASCT2 in the modulation of serine
isomers in C6 glial cells, which contain undetectable
DAO activity. A 48-hr time point was chosen so that
the effects of SRR overexpression and SRR RNAi
could also be evaluated. The results are summarized in
Table II. The main ﬁndings are as follows. 1) DAO ac-
tivity remains undetectable even if intracellular D-serine
is increased by addition of D-serine or overexpression of
SRR. 2) D-serine uptake and ASCT2 expression
decrease after addition of either serine enantiomer and
after SRR overexpression. 3) Addition of L-serine
increased the abundance of SRR but did not lead to an
increase in D-serine levels. 4) Addition of L- or D-serine
did not alter pyruvate levels. 5) Knockdown of SRR
had no effect on D-serine or its transport or pyruvate
levels. 6) Transfection and overexpression of SRR led to
increases in D-serine and pyruvate levels. These ﬁndings
are brieﬂy discussed in turn, before consideration of the
potential signiﬁcance for D-serine metabolism in glia
in vivo.
D-Serine Does Not Alter DAO Expression
or Activity in C6 Cells
In glial cells of the hindbrain, DAO is abundantly
expressed and active (Horiike et al., 1994) and is
thought to underlie the very low levels of D-serine in
the cerebellum (Schell et al., 1997). However, although
DAO mRNA and immunoreactivity have been
observed in glia (and neurons) of the forebrain (Moreno
et al., 1999; Verrall et al., 2007), DAO activity in the
cerebral cortex is minimal or undetectable. Similarly,
although C6 cells express DAO (Fig. 1B), they also
have no detectable DAO activity under basal conditions
(Table I). Our data show that incubation of the cells
with 20 mM L- or D-serine for 48 hr does not increase
Fig. 4. Measures of D-serine and pyruvate concentrations in C6
cells. A: Representative standard curve of D-serine ELISA generated
by immobilizing the amino acid at several concentrations onto assay
plates. Each data point represents the mean 6 SEM from three
experiments. B: Increased intracellular D-serine levels following a
48-hr incubation with D-serine in the culture medium (hatched
bars) compared with controls (open bars). C: No effect of 48-hr
incubation with L-serine on intracellular D-serine levels. D: Incuba-
tion with L-serine or D-serine (hatched bars) does not alter intracel-
lular pyruvate concentrations compared with paired controls (open
bars). *P < 0.05, **P < 0.001, n 5 6 for each condition.
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urable levels (Table I), nor was DAO or its activity
altered by SRR overexpression (Fig. 5C) or knockdown
(Fig. 6B). These results indicate that DAO is not a
major player in D-serine metabolism in C6 cells and
does not respond to changes in SRR expression, at least
under the various conditions studied here. As in the
forebrain, the signiﬁcance of DAO being present but
apparently inactive is unknown.
Decreased [
3H]D-Serine Uptake and ASCT2
mRNA After Incubation With Serine or SRR
Overexpression
In the absence of functional DAO, we next inves-
tigated the possible roles of D-serine transport and
expression of ASCT2 in the regulation of D-serine in
C6 cells. We found support for this, in that D-serine
uptake (Fig. 3A,B) and ASCT2 expression (Fig. 3D)
both decrease after addition of either serine isomer. A
similar but smaller effect with 1 mM serine (not shown),
which is half the concentration of the Km for ASCT2,
suggests some physiological relevance to the changes.
D-serine uptake and ASCT2 mRNA also decrease after
SRR overexpression (Fig. 5C,D). The fact that D-serine
transport (Fig. 3C) and ASCT2 expression (Fig. 3D)
were unaltered after incubation with D-proline indicates
that the effects seen in response to L- or D-serine incu-
bation are not a non-speciﬁc effect (e.g., of altered osmo-
larity). We conclude that reduced uptake is part of the
homeostatic response of C6 cells to an increased extracel-
lular concentration of serine isomers, serving to ‘‘close
the ﬂood gates’’ and prevent build up of nonphysiological
concentrations of the amino acids inside the cell.
Fig. 5. Effect of increased SRR expression in C6 cells on DAO and D-serine uptake and ASCT2 expres-
sion. A: Conﬁrmation of SRR overexpression in C6 cells transfected with recombinant SRR (CMV-
SRR). B: DAO immunoreactivity is not altered in cells overexpressing SRR. C: [
3H]D-serine uptake
into C6 cells is reduced in cells overexpressing SRR. D: ASCT2 mRNA is decreased in cells overex-
pressing SRR. **P < 0.01.
TABLE I. D-Serine and Pyruvate Concentrations in C6 Cells 48
Hours After CMV-SRR Transfection or SRR RNAi (Mean 6
SEM)
[D-serine]
(nmol/mg protein)
[Pyruvate]
(nmol/mg protein)
Control 0.37 6 0.02 15.17 6 0.34
CMV-SRR 0.57 6 0.07* 22.52 6 1.2*
Control RNAi 0.38 6 0.03 13.80 6 1.55
SRR RNAi 0.36 6 0.03 10.74 6 0.72
*P < 0.01, paired-samples t-test (n 5 6 for each condition).
1836 Sikka et al.
Journal of Neuroscience ResearchASCT2 has been proposed to transport both serine
enantiomers into C6 cells (Hayashi et al., 1997; Shao
et al., 2009), so it is tempting to conclude that a
decreased expression of ASCT2 contributes to the
reduced transport seen after incubation with L- and D-
serine, and indeed there was a signiﬁcant correlation
between [
3H]D-serine uptake and ASCT2 mRNA
(L-serine experiments: Pearson’s R 5 0.714, P 5 0.009,
n 5 12; D-serine experiments: R 5 0.730, P 5 0.007,
n 5 12). However, it remains possible that other
mechanisms, such as removal of ASCT2 from the mem-
brane, and effects on other D-serine transporters are
also involved in addition to regulation of ASCT2
expression.
Relationships Between Serine and SRR in C6 Cells
Our ﬁnal experiments focused on the response of
SRR to changes in serine concentration and vice versa.
The results were complex and not wholly as predicted
by simple models of the relationship between an enzyme
and its substrates and products.
Fig. 6. Effect of SRR RNAi in C6 cells on DAO and D-serine uptake and ASCT2 expression at 48 hr.
A: Conﬁrmation of SRR knockdown by RNAi in C6 cells transfected with plasmid sh886 compared
with controls containing transfection reagent alone. B: The reduced expression of SRR does not affect
the expression of DAO protein. C: [
3H]D-serine uptake. D: ASCT2 mRNA relative to controls. *P <
0.01.
TABLE II. Summary of the Effects of Serine Administration and Molecular Manipulations on Components of the Serine Metabolic
Pathway*
Manipulation SRR protein DAO protein [
3H]D-serine uptake ASCT2 mRNA Intracellular [D-serine] Intracellular [pyruvate]
Addition of D-serine
Addition of L-serine
SRR overexpression
SRR knockdown
*Arrows indicate a signiﬁcant increase or decrease or no effect for each manipulation on the parameters examined.
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ity, was increased 48 hr after incubation with L-serine,
suggesting that its expression is responsive to its substrate
concentration (Fig. 2A). SRR immunoreactivity was
similarly enhanced by incubation with D-serine (Fig.
2B), a ﬁnding more difﬁcult to interpret, given the vari-
ous reactions that SRR can catalyze; that is, whereas D-
serine is the product of its racemase activity, it is the
substrate for the eliminase reaction and for the proposed
reverse racemase reaction (Foltyn et al., 2005). In any
event, despite the elevated SRR, neither racemase nor
eliminase activities changed, in that D-serine did not rise
after L-serine incubation (Fig. 4C) and pyruvate levels
did not increase after either serine isomer (Fig. 4D).
These results may imply that SRR is not active in C6
cells, at least under these conditions, a suggestion sup-
ported by the RNAi experiments, which showed that an
 50% knockdown of SRR by RNAi (Fig. 6A) was also
without effect on D-serine or pyruvate concentrations
(Table II), DAO (Fig. 6B), D-serine transport (Fig. 6C),
or ASCT2 mRNA (Fig. 6D). Another possibility is that
SRR is active, accounting for the detectable basal levels
of D-serine (Fig. 4B,C), but that the exogenously
applied L-serine was converted to L-glycine by serine
hydroxymethyl transferase (SHMT; Kohl et al., 1980),
rather than to D-serine by SRR. On the other hand, if
the L-serine did undergo SRR-mediated elimination,
the resulting pyruvate might have been metabolized
by the Krebs cycle, thus precluding its detection. Paren-
thetically, SRR overexpression, induced by transfection,
did lead to increased D-serine and pyruvate levels (Table
II) in parallel with its increased abundance (Fig. 5A) and
consistent with SRR acting in racemase and eliminase
modes.
Overall, our results show evidence both for and
against the role of SRR in the metabolism of D-serine
in C6 cells and indicate the need for further studies.
First, we must address the time course of the response to
changing concentrations of serine isomers. For example,
Shoji et al. (2006a) found that SRR activity was
increased 16 hr after incubation of a human glioma cell
line with D-serine, and it may be that a similar effect in
C6 cells occurs but has subsided by the 48-hr time point
studied here. Second, we must investigate further the
relationship between SRR abundance and SRR activity.
For example, it was recently shown that redistribution of
SRR from cytosol to plasma membrane is a major deter-
minant of SRR activity in glial cells (Mustafa et al.,
2009) and in neurons (Balan et al., 2009). Any such in-
tracellular relocation would not be detected by homoge-
nate-based Western blots, so our immunoreactivity
ﬁndings may not correspond to the abundance of active
(as opposed to total) SRR. Also, there are many other
factors known to regulate SRR activity, such as pyri-
doxal phosphate (De Miranda et al., 2002), nitrosylation
(Shoji et al., 2006a,b; Mustafa et al., 2007), phosphotidy-
linositol (4,5)-bisphosphate (Mustafa et al., 2009), and
ubiquitin-mediated degradation (Dumin et al., 2006),
that have yet to be investigated in these cells.
Extrapolation to the In Vivo Situation
The existing literature and the present ﬁndings
show that the metabolism of D-serine and the roles
played by SRR, DAO, and other key molecules is com-
plex, and dependent in part on the nature and environ-
ment of the cells being studied. Clearly, this also con-
strains extrapolation to the situation pertaining in the
brain in vivo. Nevertheless, two comments in this
respect are worth making. First, our rationale for choos-
ing C6 cells for this work was that they do not contain
active DAO, even though they express the gene, a situa-
tion similar to that in the mammalian forebrain. It is
therefore of interest that 14 days’ administration of D-
serine (50 mg/kg/day) increases SRR and decreases
ASCT2 expression in rat frontal cortex (unpublished
data), providing some support for the relevance of our
ﬁndings to the in vivo situation. However it is not
yet known whether this elevation of cortical D-serine
affects endogenous SRR activity, and our in vitro ﬁnd-
ings emphasize the need for caution in making this
assumption.
Finally, our results may have some relevance with
regard to schizophrenia and its therapy. In that disorder,
NMDAR hypofunction (Olney and Farber, 1995; Coyle
et al., 2003; Harrison and Weinberger, 2005) is thought
to occur, driven in part by co-agonist deﬁciency, espe-
cially of D-serine (Hashimoto et al., 2005; Bendikov
et al., 2007). The cause of this is unknown, although
both DAO and SRR have been identiﬁed as possible
susceptibility genes (see Verrall et al., 2009). The ﬁnd-
ings have led to D-serine replenishment, DAO inhibi-
tion, and SRR enhancement being investigated as thera-
peutic strategies. Our results have three implications in
this regard. First, they suggest that targeting of D-serine
transport via ASCT2 may also be of value, comparable
to the glycine transport inhibitors also being trialled in
the disorder. Second, if D-serine levels are increased, via
supplementation or via SRR enhancement, this will not
be counteracted by induction of DAO activity. Third,
the therapeutic value of DAO inhibition may be limited,
in that its effect will likely be restricted to the cerebel-
lum, with little or no effect in the forebrain (because
DAO is inactive therein). In contrast, inhibition of D-
serine transport might be expected to show a more
widespread efﬁcacy across brain regions.
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